Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2024
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Eltrombopag for Peripheral Blood Stem Cell Harvest
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Stiftung zur Förderung medizinischer und biologischer Forschung | Novartis Pharmaceuticals Corporation | University of Erlangen-Nürnberg, Department of Biology
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomodulation With Eltrombopag in ITP
Details : Revolade (Eltrombopag Olamine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.
Product Name : Revolade
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Stiftung zur Förderung medizinischer und biologischer Forschung | Novartis Pharmaceuticals Corporation | University of Erlangen-Nürnberg, Department of Biology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2021
Lead Product(s) : Eltrombopag
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2020
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Aplastic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Aplastic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2019
Lead Product(s) : Eltrombopag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eltrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2019
Lead Product(s) : Eltrombopag
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable